Actinogen receives $9.0 million R&D tax incentive rebate
Filed with ASX · · 2 pages · English
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- ACW September 2024 quarterly activity report & Appendix 4C
- $3.0 million share purchase plan closes 1.3x oversubscribed
- ACW $11.1m capital raising to accelerate Alzheimers trial
- Pause in Trading
- ACW FY2024 results, advancing into late-stage trials
Later from Actinogen Medical
- ACW randomizes first US participant in Alzheimers trial
- ACW December 2024 quarterly activity report & Appendix 4C
- Peer-reviewed clinpharm manuscript published
- ACW HY25 results Advancing to latestage clinical development
- ACW conducts Type C meeting with FDA regarding depression
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical